GlaxoSmithKline (GSK) and Vir Biotechnology are partnering to conduct trials on an antibody for COVID-19 treatment. The clinical trial will include 1,300 patients globally and a control group receiving a placebo. Various other companies, Regeneron for instance, have released experimental antibodies to combat COVID-19 that have been effective in reducing patient virus levels and improving symptoms at an early stage. The hope for GSK and Vir Biotechnology is to create a single use antibody vaccine with long term virus-fighting abilities.
Read more here.